Pennsaid is a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries.
The trial involved more than 300 patients who were administered Pennsaid for 26 weeks and a subset of more than 100 of these patients who were administered the drug for a total of 52 weeks.
“The full analysis of data from this trial is still underway and we anticipate will be completed in the next 4-6 weeks,” said Dr Henrich Guntermann, Nuvo’s president and CEO. “The results of this study will form part of our NDA submission for Pennsaid, which remains on schedule for mid 2006.”